Prevent Diabetic Kidney Disease Among Egyptians
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Gliflozin.
- Who it may be relevant to
- Registry conditions: Diabetes Mellitus Without Complication. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The National Plan To Prevent Diabetic Kidney Disease Among Egyptians: A Prospective Multicenter Randomized Controlled Study
Overview
Study of the possibility to prevent the development of Diabetic kidney disease in type 2 diabetic patients
Detailed description
Study of the possible role of the SGLT2 inhibitors to prevent the development of frank type2 DM among prediabetic candidates.
Study of the possible role of the SGLT2 inhibitors to prevent the development of diabetic complications, namely diabetic kidney disease, diabetic retinopathy and neuropathy.
Interventions
- Drug Gliflozin
to study whether the use of gliflozin prevented diabetic complications
Primary outcome measures
- prevention of diabetic complications [Time frame: 5 years]
Eligibility criteria
Inclusion criteria
- diabetics,prediabetics
Exclusion criteria
\-
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06071208 · VCG 6